14-day Premium Trial Subscription Try For FreeTry Free
BURLINGTON, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2020 financial results and recent business highligh
Currently available studies show minimal clinical improvement compared to traditional cortisone based on primary data points.
Seeking Alpha PRO has conducted an interview with our recent Top Idea contributor, Carolina Doc, regarding their compelling thesis on Flexion Therapeutics.
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OK Boomer, Flexion Stock Is Made For You

10:31am, Friday, 24'th Jul 2020
Flexion Therapeutics (NASDAQ:FLXN) may be one of the best-kept secrets in biotech. The company has a product that addresses a condition that affects a growing number of Americans. But FLXN stock start
Does Flexion Therapeutics (FLXN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Investors need to pay close attention to Flexion (FLXN) stock based on the movements in the options market lately.
* Company reported ZILRETTA (triamcinolone acetonide extended-release injectable suspension) preliminary net sales of $15.4 million in the second quarter * Demand for ZILRETTA from healthcare p
Flexion Therapeutics (FLXN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Flexion Therapeutics, Inc.'s (NASDAQ:FLXN): Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the...
H.C. Wainwright analyst Patrick Trucchio initiated coverage with a Buy rating on Flexion Therapeutics (FLXN – Research Report) on June
In this article you are going to find out whether hedge funds think Flexion Therapeutics Inc (NASDAQ:FLXN) is a good investment right now. We like to check what the smart money thinks first before doi
Upgrades * Credit Suisse changed the rating for Allstate Corp (NYSE: ALL) from Underperform to Neutral. Allstate earned $3.54 in the first quarter, compared to $2.30 in the year-ago quarter. The sto
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE